Revenio Group Oyj (CHIX:REG1VH) ROCE %: 7.34% (As of Mar. 2026)


CHIX:REG1VH Revenio Group Oyj CHIX:REG1VH
76 GF Score
Price €16.47
GF Value €40.41
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Revenio Group Oyj ROCE %?

Revenio Group Oyj CHIX:REG1VH 76 ROCE % is 7.34% as of Mar. 2026. GuruFocus rates CHIX:REG1VH with a GF Score™ of 76/100 and a GF Value™ of €40.41 (Significantly Undervalued). The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Revenio Group Oyj's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.34%.

Revenio Group Oyj  (CHIX:REG1Vh) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Revenio Group Oyj ROCE % Related Terms

Revenio Group Oyj ROCE % Historical Data

* Premium members only.

The historical data trend for Revenio Group Oyj's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revenio Group Oyj ROCE % Chart

Revenio Group Oyj Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.76 30.16 23.04 21.45 18.98

Revenio Group Oyj Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.77 20.42 20.71 21.94 7.34
CHIX:REG1VH
76GF Score
Revenio Group Oyj CHIX:REG1VH
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revenio Group Oyj ROCE % Calculation

Revenio Group Oyj's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=23.215/( ( (141.337 - 21.601) + (150.646 - 25.782) )/ 2 )
=23.215/( (119.736+124.864)/ 2 )
=23.215/122.3
=18.98 %

Revenio Group Oyj's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=9.2/( ( (150.646 - 25.782) + (148.2 - 22.3) )/ 2 )
=9.2/( ( 124.864 + 125.9 )/ 2 )
=9.2/125.382
=7.34 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 7.34% mean?
Revenio Group Oyj (CHIX:REG1VH) has a ROCE % of 7.34% as of Mar. 2026.
Is Revenio Group Oyj's ROCE % too high?
Revenio Group Oyj's current ROCE % is 7.34%. The Medical Devices & Instruments industry median ROCE % is 2.23. Revenio Group Oyj's value of 7.34% is 229.1% above this industry median. Overall, Revenio Group Oyj has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revenio Group Oyj's ROCE % compare to ABT and SYK?
Revenio Group Oyj's ROCE % of 7.34% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Revenio Group Oyj's value of 7.34% is 229.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Revenio Group Oyj's current ROCE % of 7.34% is 229.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Revenio Group Oyj's current ROCE % is 7.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revenio Group Oyj stock overvalued right now?
Based on GuruFocus' analysis, Revenio Group Oyj (CHIX:REG1VH) is currently considered Significantly Undervalued. The stock's GF Value™ is €40.41, compared to a current price of €16.47 — trading 59.2% below its estimated fair value. The current ROCE % is 7.34% and 229.1% above the Medical Devices & Instruments industry median of 2.23. Revenio Group Oyj's overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Revenio Group Oyj (CHIX:REG1VH), the current ROCE % is 7.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revenio Group Oyj (CHIX:REG1VH) Overvalued in 2026?

Based on GuruFocus' analysis, Revenio Group Oyj stock appears to be undervalued. The current stock price of €16.47 is trading 59.2% below its estimated GF Value™ of €40.41. GuruFocus considers Revenio Group Oyj to be Significantly Undervalued.

Key valuation signals for CHIX:REG1VH:

  • ROCE %: 7.34%
  • GF Value™: €40.41 vs. price of €16.47 (59.2% below fair value)
  • GF Score™: 76/100 with 2 warning signs
  • Industry Position: 229.1% above the Medical Devices & Instruments median

No single metric tells the full story. See the CHIX:REG1VH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Revenio Group Oyj Business Description

Address Harkahaankuja 7, Vantaa, FIN, 01730
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective, easy-to-use health tech-related screening devices for detecting diseases of public health significance. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), and perimeter and fundus imaging devices under the iCare brand. Its eye care software platform, Oculo, offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company generates the majority of its revenue from the United States.
76GF Score

Get the complete analysis for CHIX:REG1VH

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.47
Price
€40.41
GF Value